Kernal Biologics is a developer of an intelligent medical platform. Kernal’s mRNA 2.0 platform can perform multi-dimensional and large-scale analysis of the transcriptome and translatome through machine learning, thereby identifying unique cells that can be targeted on various cells. genetic code. The first products on the mRNA 2.0 platform will primarily target the development of immunotherapies in the field of cancer. Kernal Biologics today announced the completion of a $25 million Series A financing. Terms of the deal were not disclosed.
This article is reproduced from: https://www.itjuzi.com/investevent/13330776
This site is for inclusion only, and the copyright belongs to the original author.